Previstage(TM) GCC to be presented at ASCO GI

Ticker Symbol: CUR

QUEBEC CITY, Jan. 12 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a
life sciences company commercializing high-value cancer diagnostic tests and
delivering lab services, and its wholly-owned subsidiary, DiagnoCure Oncology
Laboratories based in West Chester, PA, near Philadelphia, will exhibit at the
American Society of Clinical Oncology The Gastrointestinal Cancers Symposium
(ASCO GI) beginning January 15th in San Francisco, California. The Company is
also sponsoring an Independent Satellite Symposium to be conducted adjunct to
ASCO GI on January 14th, during which molecular markers for colorectal cancer
will be discussed.
DiagnoCure will take this opportunity to meet surgeons, oncologists,
radiologists and other clinical specialists who focus on treating patients
with colorectal and other cancers of the gastrointestinal tract, and increase
their awareness about its Previstage(TM) GCC Colorectal Cancer Staging Test,
launched last August in the United States.
In particular, DiagnoCure has provided an unrestricted educational grant for
the Independent Satellite Symposium, "Molecular Markers and Prognosis of
Patients with Colorectal Cancer". Three members of DiagnoCure's Strategic
Advisory Board, Dr. Edith P. Mitchel (Thomas Jefferson University), Dr.
Stanley Hamilton (University of Texas M.D. Anderson Cancer Center) and Dr.
Daniel Sargent (Mayo Clinic), will be speaking about patients with colorectal
cancer, including a review of the value of colorectal cancer staging. Medical
Education Resources, Inc., an ACCME accredited provider, designates this
presentation as a creditable educational activity.

OneMedForum Annual Meeting

Also, on January 14th, the Company will be exhibiting and Mr. John Schafer,
President and CEO, will be presenting a company overview during the 2nd Annual
OneMedForum, at 3:30 p.m. (ET), at the Sir Francis Drake Hotel, in San
Francisco (CA).
The financial forum will bring together promising emerging healthcare and life
science companies with strategic and venture investors focused on new
technologies, emerging and micro cap public companies.

About Previstage(TM) GCC

Every year in North America, 174,000 people are diagnosed with colorectal
cancer, and 142,000 colorectal cancer surgeries are performed. Staging a
patient with colorectal cancer is crucial because it determines the patient's
course of treatment after the surgery. Current standard of care requires that
pathologists microscopically examine a thin slice of tissue from each of the
lymph nodes harvested during the patient's surgery to see if cancer has
spread. Currently, up to 30 percent of patients with no pathologically
positive lymph nodes (stage I and II cancers) later develop recurrent disease,
presumably through occult metastases that have escaped detection. Most of
these patients do not receive additional therapies such as chemotherapy. With
a detection capacity that is close to 100,000 more sensitive than microscopic
methods, Previstage(TM) GCC provides clinicians with significantly more
accurate information for staging a patient with colorectal cancer that will
increase their confidence in making critical treatment decisions.
Clinical study data supports the potential for the GCC test to improve the
current staging of colorectal patients. The National Cancer Institute
sponsored a five-year prospective clinical trial of GCC testing in colorectal
cancer patients. This study has been recently completed and the Company's
collaborators at Thomas Jefferson University are presenting the results at
major medical conferences throughout the year. The Previstage(TM) GCC
Colorectal Cancer Staging Test is a laboratory-developed test and its
performance characteristics have been determined by DiagnoCure Oncology
Laboratories.

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value
cancer diagnostic tests and delivering laboratory services that increase
clinician and patient confidence in making critical treatment decisions. In
2008, DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc.,
launched the Previstage(TM) GCC Colorectal Cancer Staging Test, the first GCC
based molecular test for the management of colorectal cancer. The Company also
has a strategic alliance with GenProbe (NASDAQ: GPRO) for the development and
commercialization of a second-generation prostate cancer test using PCA3,
DiagnoCure's proprietary molecular marker. This test is also available through
laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from
GenProbe, in Europe as the CE-marked PROGENSA(TM) PCA3 in vitro assay, and in
Canada. For more information, visit www.diagnocure.com.

Forward-looking statements

This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein.
SOURCE DIAGNOCURE INC.

Investors: J.F. Bureau, CFA, Sr. Vice President and CFO, DiagnoCure Inc.,
(418) 527-6100; Media: Isabelle Taschereau, Associate Director, Corporate
Affairs, DiagnoCure Inc., (418) 527-6100, communications@diagnocure.com